- Conditions
- Alzheimer Disease
- Interventions
- Raloxifene
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 55 Years to 90 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 45
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Vasomotor Symptoms, Endometrial Safety
- Interventions
- Raloxifene, medroxyprogesterone acetate, estrogen, 17 beta estradiol
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 50 Years to 70 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Osteoporosis, Post-Menopausal
- Interventions
- raloxifene, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 5
- States / cities
- La Jolla, California • Menlo Park, California • Oakland, California + 2 more
- Conditions
- Endometrial Cancer
- Interventions
- raloxifene
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- Sample collection, Patient-reported outcomes
- Other · Behavioral
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Postmenopause
- Interventions
- conjugated estrogens, Raloxifene, exercise plus mild caloric restriction for weight loss
- Drug · Behavioral
- Lead sponsor
- National Institute on Aging (NIA)
- NIH
- Eligibility
- 50 Years to 70 Years · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Breast Cancer
- Interventions
- Raloxifene - Usual, Raloxifene - Study
- Drug
- Lead sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- Industry
- Eligibility
- 24 Years to 64 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Osteoporosis, Post-Menopausal
- Interventions
- Raloxifene, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 85 Years · Female only
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Omaha, Nebraska
- Conditions
- Polycystic Ovarian Syndrome
- Interventions
- Raloxifene, Clomiphene
- Drug
- Lead sponsor
- Bruce Lessey
- Other
- Eligibility
- 18 Years to 36 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Raloxifene HCL, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- Up to 80 Years · Female only
- Enrollment
- 7,705 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 1999
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Tamoxifen
- Drug
- Lead sponsor
- Seth Lerner
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Endometriosis, Pelvic Pain
- Interventions
- Raloxifene
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- Female only
- Enrollment
- 612 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1998 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- Risedronate, Raloxifene, Placebo
- Drug · Other
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- Up to 65 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Osteoporosis
- Interventions
- Raloxifene, Zoledronic Acid
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 18,028 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- raloxifene, evaluation of cancer risk factors
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 23 Years to 47 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Healthy
- Interventions
- Estradiol followed by progesterone, Raloxifene
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Breast Cancer
- Interventions
- measuring estradiol and progesterone levels in saliva
- Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Osteoporosis, Postmenopausal
- Interventions
- teriparatide, raloxifene HCl, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years to 80 Years · Female only
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- Maywood, Illinois • Portland, Oregon
- Conditions
- Alzheimer Disease
- Interventions
- raloxifene, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 4
- States / cities
- Santa Rosa, California • Stanford, California • Springfield, Illinois + 1 more
- Conditions
- Breast Cancer
- Interventions
- Raloxifene followed by combination therapy, Exemestane followed by combination therapy
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- Raloxifene, Tamoxifen
- Drug
- Lead sponsor
- NSABP Foundation Inc
- Network
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 19,747 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 492
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more
- Conditions
- BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
- Interventions
- raloxifene, Finasteride
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Postmenopause
- Interventions
- Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 22
- States / cities
- Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
- Conditions
- Osteoporosis
- Interventions
- lasofoxifene, raloxifene, Placebo
- Drug
- Lead sponsor
- Ligand Pharmaceuticals
- Industry
- Eligibility
- 48 Years to 75 Years · Female only
- Enrollment
- 540 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2005
- U.S. locations
- 72
- States / cities
- Albany, California • Berkeley, California • La Jolla, California + 49 more